Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization of Beta-lactam Dosing in Critically Ill Patients With Suspected or Documented Antimicrobial Resistant Gram-Negative Infections With Cystatin-C (OPTIMIZE-GNI)

NCT06709521 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT06709521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06709521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization of Beta-lactam Dosing in Critically Ill Patients With Suspected or Documented Antimicrobial Resistant Gram-Negative Infections With Cystatin-C (OPTIMIZE-GNI)
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 4
Overall status
Completed
Start date
February 12, 2025
Completion date
July 2, 2026
Enrollment
161 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infection